Care needed in interpretation of cancer survival measures

Menée à partir de données portant sur 7,2 millions d'adultes atteints d'un cancer primitif invasif diagnostiqué entre 1971 et 2011 en Angleterre et au Pays de Galles, cette étude analyse l'évolution du taux de survie nette à 1, 5 et 10 ans sur une période de 40 ans

Résumé en anglais

Cancer patient survival obtained from population-based cancer studies is the optimum method to monitor and assess the effectiveness of patient care. Consideration of these estimates in conjunction with estimates of cancer incidence and mortality is still important. As a result, there is much interest in the assessment of progress in terms of cancer survival. Quantification of the improvements in cancer patient survival because of successes in some areas, such as treatment, diagnostic techniques, and awareness or screening campaigns, is of paramount importance to health-care officials, health policy makers, and charities supporting these developments in cancer control. However, to make a fair comparison—to compare like with like—is essential to assess progress accurately.